SGCB and hydrops fetalis: Vericiguat is a direct stimulator of sGC developed as a first-in-class therapy to reduce the risk of cardiovascular death and hospitalization for HF following a worsening HF event, in adults with symptomatic chronic HF and LVEF < 45%.